TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
TapImmune Inc. is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of...
View full press release